|Bid||11.08 x 800|
|Ask||11.09 x 1800|
|Day's Range||9.56 - 11.28|
|52 Week Range||7.26 - 21.39|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.25|
Although optimists currently believe we're getting past the worst of the coronavirus pandemic, Dynavax Technologies (NASDAQ: DVAX) shares saw a lift Monday on positive vaccine news. A popular coronavirus stock in the worst days of the outbreak, an important business partner of the company had some good regulatory news to impart. Dynavax investors took this to heart by pushing their company's stock up by nearly 2.3% on the day, while the S&P 500 index sank by 0.4%.
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022.
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: